TY - JOUR
T1 - Adverse Effects of Clopidogrel
T2 - a Cross Sectional Study of the FDA Adverse Event Reporting System Database
AU - Al-Saikhan, Fahad
AU - Ahmad, Nehad
AU - Abd-Elaziz, Mohamed
AU - Iqbal, Muhammad Shahid
N1 - Publisher Copyright:
© 2022, Colegio de Farmaceuticos de la Provincia de Buenos Aires. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Unexpected effects could also occur after the marketing of clopidogrel. So, it is necessary to ensure clopidogrel continued safety once it reaches the general population. The present study aimed to de-scribe the adverse effects reports of clopidogrel during the previous years. It included a descriptive analysis of all reported AEs associated with clopidogrel using the FDA Adverse Event Reporting System. From 1998 to the end of 2021, a total of 21566 reports of clopidogrel adverse events were submitted to FAERS. Most of the reports were submitted by healthcare professionals (88.43%). The most reported clopidogrel adverse reactions were anemia (7.88%), drug interactions (7.48%), gastrointestinal hemorrhage (6.27%), and dys-pnea (5.06%). Nowadays, clopidogrel is widely used in clinical practice, so the occurrence of different side effects particularly the hematological side effects should be considered by healthcare providers. Moreover, the pharmacists should check for the interactions between clopidogrel and other medications before dispens-ing clopidogrel.
AB - Unexpected effects could also occur after the marketing of clopidogrel. So, it is necessary to ensure clopidogrel continued safety once it reaches the general population. The present study aimed to de-scribe the adverse effects reports of clopidogrel during the previous years. It included a descriptive analysis of all reported AEs associated with clopidogrel using the FDA Adverse Event Reporting System. From 1998 to the end of 2021, a total of 21566 reports of clopidogrel adverse events were submitted to FAERS. Most of the reports were submitted by healthcare professionals (88.43%). The most reported clopidogrel adverse reactions were anemia (7.88%), drug interactions (7.48%), gastrointestinal hemorrhage (6.27%), and dys-pnea (5.06%). Nowadays, clopidogrel is widely used in clinical practice, so the occurrence of different side effects particularly the hematological side effects should be considered by healthcare providers. Moreover, the pharmacists should check for the interactions between clopidogrel and other medications before dispens-ing clopidogrel.
KW - adverse event reporting
KW - clopidogrel
KW - FAERS
KW - post-marketing
UR - http://www.scopus.com/inward/record.url?scp=85133828132&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85133828132
SN - 0326-2383
VL - 41
SP - 1388
EP - 1391
JO - Latin American Journal of Pharmacy
JF - Latin American Journal of Pharmacy
IS - 7
ER -